BCL2L12 and neoplasm: Given the low-level expression of Bcl2L12 in the adult brain, its consistently elevated expression in glioblastoma tumors, the profound negative correlation of its expression with patient survival, and ability to inhibit the p53 tumor suppressor, the inhibition of Bcl2L12 expression represents a rational therapeutic strategy to restore wild-type p53 tumor suppression in glioblastoma.